| CONTACTS: |
César García,
President and Chief Executive Officer |
|
818-709-1244 x 7123
|
|
-or-
|
|
Ron Stabiner, The Wall Street Group, Inc. |
|
212-888-4848 |
CHATSWORTH, Calif., May 14, 2007 - IRIS International, Inc. (NASDAQ GM: IRIS)
today announced that President and Chief Executive Officer César García will deliver a presentation to investors at the 4th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 23,
2007, at 9:20 a.m. Central time, in the Copenhagen Room at the Radisson Plaza Hotel, 35 South 7th St., in Minneapolis, Minn.
"We are pleased to once again be invited to make a presentation at the Craig-Hallum Institutional Investors Conference," Mr. García stated. "IRIS is
leveraging its core competencies in cell morphology analysis, chemistry and ultra-sensitive protein detection to develop new technology platforms that will significantly add to its core businesses while
simultaneously generating revenues derived from new market opportunities in urine microscopy, body fluids testing and hematology. We look forward to the continuing process of sharing this vision with the
investment community."
More than 50 companies from a variety of industries, including medical device manufacturers, will participate in the conference sponsored by Craig-Hallum, an institutional
equity and investment-banking firm. During the conference, executives from each company will participate in private one-on-one sessions with select institutional investors. The conference is only for clients
of Craig-Hallum and the sessions will not be webcast.
THE COMPANY
IRIS International, Inc. (www.proiris.com), based in Chatsworth, Calif., is a leading developer, manufacturer, and marketer of
medical devices, diagnostic systems and consumables. The Iris Diagnostics Division (www.irisdiagnostics.com) is a leader in automated
urinalysis technology with systems in major medical institutions throughout the world. The Company's Sample Processing business unit (formerly the StatSpin® subsidiary)
(www.statspin.com), based in Westwood, Mass., manufactures innovative centrifuges and blood analysis products. The Iris Molecular Diagnostics (IMD)
Subsidiary, based in San Diego, Calif., develops innovative ultra-sensitive diagnostics and sample processing products with applications in the urinalysis, oncology and infectious disease markets.
Advanced Digital Imaging Research, LLC (ADIR), based near Houston, Tex., is the Company's imaging research and development subsidiary.
SAFE HARBOR PROVISION
This news release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, the Company's views on future financial performance, market growth, capital requirements, new product introductions and acquisitions, and are generally
identified by phrases such as "thinks," "anticipates," "believes," "estimates," "expects," "intends," "plans," and similar words.
Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking
statement. These statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the
Company's industry, R&D initiatives, competition and capital requirements. Other factors and uncertainties that could affect the Company's forward-looking statements include, among other things, the
following: identification of feasible new product initiatives, management of R&D efforts and the resulting successful development of new products and product platforms; including obtaining any required
governmental approvals; acceptance by customers of the Company's products; integration of acquired businesses; substantial expansion of international sales; reliance on key suppliers; the potential need for
changes in long-term strategy in response to future developments; future advances in diagnostic testing methods and procedures; potential changes in government regulations and healthcare policies, both of which
could adversely affect the economics of the diagnostic testing procedures automated by the Company's products; rapid technological change in the microelectronics and software industries; and competitive
factors, including pricing pressures and the introduction by others of new products with similar or better functionality than our products. These and other risks are more fully described in the Company's
filings with the Securities and Exchange Commission, including the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in conjunction herewith
for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements. The Company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future events or otherwise.
